Skip to content

Interventional study with GYIDE system for ablation of fibroids under ultrasound guidance.

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids performance evaluation of GYIDE - NIL

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070536
Enrollment
30
Registered
2024-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N948- Other specified conditions associated with female genital organs and menstrual cycle

Interventions

Intervention1: Radiofrequency ablation for uterine fibroid using GYIDE: GYIDE: GYIDE is intended for processing diagnostic ultrasound imaging to provide planning and positional guidance for transcervi

Sponsors

Nesa Medtech Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women in reproductive age who have completed family planning with symptomatic uterine fibroid (menorrhagia, heavy menstrual bleeding) for at least 2 months and as confirmed by USG. 2.Patients presenting with 1-4 fibroids of FIGO types 2, 3, 4, and/or type 2-5, with diameter of 1.0 cm and up-to 6.0 cm. 3.No desire for future fertility 4.Women willing to provide informed consent for participation in the study and willing to undergo this RFA using (GYIDE) and adhere to follow-up requirements

Exclusion criteria

Exclusion criteria: 1.Presence of a single polyp less than 1.5 cm, or multiple polyps of any size, within the uterine cavity. 2.Any abnormality of the endometrial cavity that obstructs access of the handpiece 3.Total uterine volume more than 1000 cc. 4.Pregnancy. 5.Presence of type 0 fibroids, unless greater than 1 cm in diameter. 6.Presence of an extrauterine pelvic mass that has not been diagnosed as benign. 7.Multiple uterine scars. 8.Congenital uterine abnormality 9.Previous procedure for fibroids or heavy menstrual bleeding other than myomectomy (example: endometrial ablation). 10.Confirmed abdominal or pelvic malignancy within the previous five years 11.Active pelvic infection or current positive testing for pelvic gonorrhea or chlamydia, UTI.

Design outcomes

Primary

MeasureTime frame
The main aim of this study is to evaluate the device ability to ablate the fibroid while avoiding damage to serosa or surrounding organs.Timepoint: 1.To capture the serosa in the hysterectomized specimens(visit 1- day of procedure). 2.To evaluate the ablated region of target fibroid(visit 1- day of procedure).

Secondary

MeasureTime frame
To determine the total time required for GYIDE procedureTimepoint: To record the time for mapping of fibroids(visit 1- day of procedure). To record the time required for ablation for each of the fibroids(visit 1- day of procedure).

Countries

India

Contacts

Public ContactLakshmi Bai P

Nesa Medtech Private Limited

sreekar@nesamedtech.com9019708139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026